Clinical trials: Double-blind Randomized Controlled Study
Huntington Disease
Study of WVE-003 in Patients With Huntington's Disease
This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of WVE-003 in adult patients with early-manifest HD who…
- Trial name
- NCT05032196
- Testing
- SAD: 30mg WVE-003, SAD: 60mg WVE-003, SAD: 90mg WVE-003
- Where
- 23 sites in Australia, Canada and 8 more
- Volunteers
- 47 people
- Sponsor
- Wave Life Sciences USA, Inc.
Chronic Low Back Pain
A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain
The objectives of this study are to examine the safety, tolerability, and efficacy of repeated topical administration of AB001 topical patches for the treatment of chronic low back pain.
- Trial name
- NCT02436824
- Testing
- AB001 patch
- Where
- 9 sites in United States
- Volunteers
- 146 people
- Sponsor
- Frontier Biotechnologies Inc.
Psoriatic Arthritis
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are…
- Trial name
- EXCEED 1 (NCT02745080)
- Testing
- Secukinumab, Adalimumab
- Where
- 156 sites in United States, Australia and 24 more
- Volunteers
- 853 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
A First in Human Trial Evaluating THB335 in Healthy Participants
This study is a double blind, randomized, placebo-controlled, Phase 1 study in three parts: single ascending doses and food effect (Part 1), multiple ascending doses (Part 2) and Relative Bioavailability of Two Formulations (Part…
- Trial name
- NCT06425861
- Testing
- THB335 single dose, THB335 fasted/fed, THB335 multiple dose
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Third Harmonic Bio, Inc.
Muscle Wasting (Atrophy) After Hip Fracture Surgery
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
- Trial name
- NCT02152761
- Testing
- bimagrumab
- Where
- 53 sites in United States, Argentina and 17 more
- Volunteers
- 251 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson Disease
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
This trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients…
- Trial name
- NCT06822517
- Testing
- VENT-02
- Where
- 23 sites in United States
- Volunteers
- 29 people
- Sponsor
- Ventus Therapeutics U.S., Inc.
Migraine Disorders
Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)
Study to understand the effects of migraine treatments on blood pressure in participants with migraine. The primary hypothesis is that the effect on semi-recumbent mean arterial pressure following the coadministration of…
- Trial name
- NCT00701389
- Testing
- telcagepant potassium, sumatriptan
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus With Diabetic Nephropathy
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
To evaluate the safety and efficacy of IW-1973 in patients with type 2 diabetes mellitus with albuminuria who are on a stable regimen of renin-angiotensin system inhibitors.
- Trial name
- NCT03217591
- Testing
- IW-1973
- Where
- 54 sites in United States
- Volunteers
- 156 people
- Sponsor
- Akebia Therapeutics
Major Depressive Disorder (MDD), Depression in Adults
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
- Conditions
- Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
- Trial name
- EMBRACE (NCT06793397)
- Testing
- CYB003, Psychological Support
- Where
- 79 sites in United States, Australia and 6 more
- Volunteers
- 330 people
- Sponsor
- Cybin IRL Limited
Aging
aKLmRNA-mediated Protein Replacement Therapy
This is a Phase 1b randomized, double-blind, placebo-controlled study to assess the safety and tolerability of a proprietary aKLmRNA formulated in lipid nanoparticles. Approximately 21 subjects will be enrolled.
- Trial name
- NCT07544420
- Testing
- aKLmRNA (AKL003)
- Where
- Honduras
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Klothea Bio Inc
Ankylosing Spondylitis
Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis
Study of the efficacy and safety of adalimumab compared with placebo in adult Chinese participants with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal…
- Trial name
- NCT01114880
- Testing
- adalimumab
- Where
- 9 sites in China
- Volunteers
- 344 people
- Sponsor
- Abbott
Cognitive Dysfunction, Schizophrenia
TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia
Schizophrenia affects approximately 1% of the population worldwide, and in about 80% of cases, it is a lifelong, disabling illness.
- Trial name
- NCT01003379
- Testing
- TC-5619
- Where
- 16 sites in United States, India
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Plaque Psoriasis
A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, dose-escalation Phase Ib study to evaluate the safety, tolerability, and pharmacokinetics of HB0017 following multiple dose in patients with moderate to severe plaque…
- Trial name
- NCT05442788
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Healthy Volunteer
Safety, Tolerability, and Dose Response of VNA-318 in Healthy Males
This is a phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (SAD) and multiple ascending doses (MAD) of VNA-318 in…
- Trial name
- NCT06721091
- Testing
- VNA-318
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- VANDRIA
Borderline Personality Disorder
Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population
PORTICO is a Phase IIb study to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population.
- Trial name
- NCT04932291
- Testing
- vafidemstat
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 211 people
- Sponsor
- Oryzon Genomics S.A.
Atopic Eczema
Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema
The aim of the study is an intra-individual comparison of skin conditions in addition to a patient based assessment of product appearance in the topical treatment of atopic eczema.
- Trial name
- NCT01119313
- Testing
- LAS 41002, Active
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Almirall, S.A.
GNE Myopathy, Hereditary Inclusion Body Myopathy
A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy
GNE myopathy or hereditary inclusion body myopathy (HIBM) is a severe progressive metabolic myopathy caused by a defect in the biosynthetic pathway for sialic acid (SA).
- Trial name
- GNE Myopathy (NCT01517880)
- Testing
- Sialic Acid Extended Release (SA-ER)
- Where
- 4 sites in United States, Israel
- Volunteers
- 46 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Diabetes Mellitus, Type 2
A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)
This study will test the effectiveness and safety of treatment with MK-0893 in combination with other drugs commonly used to treat type 2 diabetes for a duration up to 13 weeks.
- Trial name
- NCT00631488
- Testing
- MK-0893, Sitagliptin, Metformin
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
Safety Issues
A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults
This is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and PK/PD profiles of RG002C0106 injection in healthy adult subjects.
- Trial name
- NCT06494527
- Testing
- RG002C0106
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Type 2 Diabetes Mellitus
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
The goal of this study is to demonstrate that leucine in combination with a low does of metformin can serve as an adjunct to diet and exercise to improve blood glucose levels in type 2 diabetic subjects.
- Trial name
- NCT02151461
- Testing
- Low Metformin, Metformin, Mid Metformin
- Where
- 9 sites in United States
- Volunteers
- 96 people
- Sponsor
- NuSirt Biopharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.